Recent Company News

• 10:02 AM ET Nov 10, 2025
  

  Transcript Intelligence: Teva Pharmaceutical at UBS Global Healthcare Conference ($24.12, +0.15)

• 10:45 PM ET Nov 07, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 06:04 PM ET Nov 07, 2025
  

  Teva presents new data from IMPACT-TD Registry at 2025 Neuroscience Education Institute Fall Congress ($23.97, 0.00)

• 05:59 PM ET Nov 07, 2025
  

  AUSTEDO(R) (deutetrabenazine) tablets and AUSTEDO XR(R) (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

• 09:17 AM ET Nov 06, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:59 AM ET Nov 06, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:08 AM ET Nov 06, 2025
  

  Teva Canada comments on recent RAMQ reimbursement update for ADHD treatments ($24.60, 0.00)

• 08:05 AM ET Nov 06, 2025
  

  Teva Canada Welcomes RAMQ Reimbursement Update Supporting Access to ADHD Treatments

• 05:26 PM ET Nov 05, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:45 PM ET Nov 05, 2025
  

  FactSet Podcast - Evening Market Recap, 5-Nov